Please login to the form below

Not currently logged in
Email:
Password:

Silence Therapeutics appoints Michael Khan as chief medical adviser

Will advise on translational research for its siRNA-based therapeutics

UK-based biotech Silence Therapeutics has appointed Dr Michael Khan as the company's chief medical adviser.

Dr Khan is an associate professor of medicine at the University of Warwick and a consultant physician at University Hospitals.

In his role as adviser, he will help Silence develop translational clinical research involving its siRNA-based therapeutics for the treatment of orphan diseases, and those conditions with current unmet medical need.

“I believe that Silence Therapeutics core technologies are uniquely positioned to fulfil these needs,” said Dr Khan.

Dr Khan's previous roles include head of molecular medicine at Warwick University, where he helped develop various projects in cell and molecular biology.

His work has covered cancer and diabetes, and he has written several books on the subjects. He also teaches postgraduates and undergraduates in medicine and biological sciences in these areas.

In addition, Dr Khan is a fellow of the Royal College of Physicians of London and a member of the Association of Physicians, HEART-UK and Diabetes UK.

“Michael's medical, clinical and regulatory experience will be invaluable as we look to commercialise our prospects,” said Klaus Giese, chief scientific officer of Silence.

20th September 2012

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...

Infographics